Generic competition isn’t just a legal event—it’s a business strategy.
For years, the industry has treated patent cliffs like weather: predictable, unavoidable, and managed with the right hedges. But the real story behind many “unexpected” delays in …

Patients aren’t asking “about patents.” They’re asking: “Will my medicine still work?”
If you’ve spent any time around healthcare—clinics, pharmacies, payer conversations—you’ve seen the real question hiding behind the legal jargon: drug switching.
I…

GPT, Rosalind, and Generic Drugs: What OpenAI’s Life-Sciences Model Actually Changes
The life-sciences industry loves a good demo. A model that can read, reason, and draft—fast. A new interface that promises to compress months of work into days. But wh…

Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before LOE Hits
The patent cliff isn’t a cliff. It’s a countdown.
And in pharma, the companies that win aren’t always the ones with the best science—they’re the ones with the best timing. T…

🚨 The drug patent cliff just got a new kind of accelerant.
OpenAI’s GPT and Rosalind—two names that sound like they belong in a sci‑fi pitch deck—are now being positioned as tools that can compress the time between “we think this molecule might wo…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—months before launch—when a competitor files a Paragraph IV c…

Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s why.
If you’re building a launch plan, underwriting pipeline value, or negotiating market access in the Gulf Cooperation Council (GCC), you already know the uncomfor…

Your competitor isn’t “just innovating.” They’re often extending.
In pharma, the most consequential moves rarely look dramatic on the surface. A new label claim. A “minor” formulation tweak. A fresh patent filing that seems technical—until you realize …